CKM syndrome is a relatively new framework adopted by the American Heart Association to describe what happens when metabolic dysfunction, chronic kidney disease, and cardiovascular disease become entangled in a self-reinforcing spiral. Obesity drives insulin resistance, insulin resistance promotes inflammation and vascular damage, declining kidney function accelerates hypertension and fluid overload, and the failing heart in turn worsens kidney perfusion. The syndrome is formally staged from 0 to 4, with stage 0 representing no risk factors and advanced stages reflecting established metabolic, renal, and cardiac pathology. Because the condition develops silently over decades, clinicians have long sought biomarkers that can flag patients on the trajectory toward advanced disease while intervention is still possible. Existing markers capture fragments of the picture — glycated hemoglobin reflects glucose control, estimated glomerular filtration rate reflects kidney function, and lipid panels reflect cholesterol metabolism — but none integrates the inflammatory and nutritional dimensions that underpin the entire syndrome.

That is precisely the gap the RAR index is designed to fill. Red blood cell distribution width, or RDW, is a standard parameter reported by every automated hematology analyzer; it quantifies the variability in the size of circulating red blood cells. Elevated RDW is a well-documented marker of systemic inflammation, oxidative stress, and disordered iron metabolism, and it has repeatedly been linked to worse outcomes in heart failure, coronary disease, and atrial fibrillation. Albumin, meanwhile, is the most abundant protein in blood plasma, synthesized by the liver, and serves as a sensitive barometer of nutritional status, liver synthetic capacity, and the systemic inflammatory response — inflammation suppresses albumin production and increases its leakage from the vascular compartment. Dividing RDW by albumin concentration therefore yields a composite measure in which a rising numerator signals inflammatory stress and a falling denominator signals nutritional decline, producing a single number that climbs as both pathologies worsen.

To test whether this composite index tracks CKM syndrome severity, the research team, led by investigators at Zhejiang University School of Medicine in Hangzhou, China, turned to two complementary population resources. The first was the National Health and Nutrition Examination Survey (NHANES), a continuous program of the US National Center for Health Statistics that combines standardized physical examinations with laboratory testing in a nationally representative sample; the team analyzed NHANES cycles from 1999 to 2018, encompassing 32,068 participants. The second was the UK Biobank, a prospective cohort of half a million British adults recruited between 2006 and 2010, from which 110,123 participants with the required baseline data were included. Together the two cohorts provided 142,191 individuals, allowing the researchers to test their hypotheses both cross-sectionally, in a snapshot of the population at a single time point, and longitudinally, by following participants forward in time to see who developed cardiovascular disease.

The analytical strategy was deliberately rigorous. Because CKM syndrome is staged rather than binary, the team used multinomial logistic regression to model the odds of belonging to each progressively more severe stage as RAR increased. For the longitudinal component, they applied multivariate Cox proportional hazards regression, the standard framework for time-to-event analysis, to estimate how baseline RAR predicted the future occurrence of cardiovascular disease overall and of specific endpoints including coronary heart disease, heart failure, atrial fibrillation, peripheral artery disease, and stroke. To probe the shape of the dose-response relationship, they employed restricted cubic splines, a flexible modeling technique that can reveal nonlinear patterns without imposing a rigid linear assumption. All models were adjusted for the standard battery of confounders — age, sex, body mass index, smoking status, hemoglobin A1c, high-density lipoprotein cholesterol, estimated glomerular filtration rate, and the urinary albumin-to-creatinine ratio among them — and the authors accounted for multiple testing using false discovery rate control.

The results were strikingly consistent across both cohorts. In the cross-sectional analyses, each standard deviation increase in RAR was associated with a 47 percent greater odds of advanced CKM stages in the NHANES population, with an odds ratio of 1.47 and a 95 percent confidence interval of 1.42 to 1.54. In the UK Biobank, the corresponding odds ratio was 1.23 with a confidence interval of 1.21 to 1.25 — a somewhat smaller but still highly significant effect, and one that all p-values below 0.001 render statistically robust. The difference in magnitude between the two cohorts is itself informative: NHANES captures a nationally representative sample with wide variation in metabolic health, whereas UK Biobank participants tend to be healthier than the general British population, a well-known phenomenon that typically attenuates risk estimates. That the association survived in both settings, and in both a cross-sectional and a longitudinal design, strengthens the case that RAR is genuinely tracking disease biology rather than some artifact of a single population or study design.

The longitudinal findings extend the story beyond staging into prediction. Elevated baseline RAR predicted an increased risk of incident cardiovascular disease overall, with a hazard ratio of 1.12 per standard deviation increase and a 95 percent confidence interval of 1.10 to 1.14. When the investigators broke cardiovascular disease down into its component diagnoses, the signal persisted across the board: coronary heart disease, heart failure, atrial fibrillation, peripheral artery disease, and stroke were all individually predicted by higher RAR, again with p-values below 0.001. Restricted cubic spline analysis indicated that the relationship between RAR and CKM stages held across the observed range of the index, supporting its use as a continuous risk variable rather than requiring an arbitrary cutoff. Notably, the association was strongest in CKM stages 2 and 3 — the transitional phases in which metabolic risk factors have crystallized into organ-level pathology but before overt cardiovascular events have occurred. This is exactly the window in which aggressive management of blood pressure, glucose, lipids, and kidney function can change the trajectory of the disease.

The biological plausibility of these findings rests on the convergence of two well-characterized pathways. Chronic low-grade inflammation is now recognized as a central driver of atherosclerosis, insulin resistance, and kidney fibrosis; inflammatory cytokines perturb erythropoiesis and iron homeostasis, widening the distribution of red cell sizes, while simultaneously suppressing hepatic albumin synthesis. Poor nutrition, another hallmark of advancing CKM syndrome, independently lowers albumin. An elevated RAR therefore functions as a readout of the inflammatory-nutritional axis that sits at the heart of the syndrome’s pathophysiology. The authors argue that this integrative quality is what gives RAR its stage-dependent behavior: as the syndrome progresses from isolated risk factors to multisystem organ involvement, both inflammation and nutritional compromise intensify, and the index rises in step.

For clinical practice, the appeal of RAR is practical as much as scientific. Both RDW and albumin are measured routinely in complete blood counts and metabolic panels, meaning the index can be calculated at no additional cost from data already sitting in the electronic health record. The study’s authors conclude that RAR serves as a robust, stage-dependent biomarker for higher CKM stages and cardiovascular incidence, with potential utility for risk stratification of CKM severity and for guiding early cardiovascular intervention strategies. They are careful to frame the work as associative rather than causative — an elevated RAR does not itself damage the heart or kidneys, but it may reveal the underlying inflammatory and metabolic fire that does. The study also carries the usual caveats of observational research: residual confounding cannot be excluded, NHANES and UK Biobank populations are predominantly of European and American ancestry, and the UK Biobank’s healthy-volunteer effect may limit generalizability to the sickest patients. Prospective validation in diverse cohorts and demonstration that RAR-guided management improves outcomes would be the necessary next steps before the index earns a place in formal guidelines.

Even so, the study adds momentum to a broader shift in cardiology and nephrology toward cheap, integrative biomarkers that capture multisystem risk. As the American Heart Association’s CKM staging framework spreads into routine care, tools that can assign patients to a stage quickly and inexpensively will be in growing demand. A ratio derived from two numbers that already appear on nearly every admission bloodwork — one measuring how unevenly a patient’s red blood cells are built, the other measuring how well their liver and nutrition are holding up against systemic disease — may prove to be exactly such a tool, flagging the silent progression of cardiovascular-kidney-metabolic syndrome years before the first heart attack or stroke makes it impossible to ignore.

Subject of Research: Association between the red blood cell distribution width to albumin ratio and cardiovascular-kidney-metabolic syndrome stages and cardiovascular disease risk

Article Title: Ratio of red blood cell distribution width to albumin concentration and risk of cardiovascular-kidney-metabolic syndrome stages

Article References: Zhou, X., Wu, S., Lu, Y., Zhu, S., Liu, C., Shen, J., Xiang, M., Wu, X., & Xie, Y. (2026). Ratio of red blood cell distribution width to albumin concentration and risk of cardiovascular-kidney-metabolic syndrome stages. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02595-2

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02595-2

Keywords: cardiovascular-kidney-metabolic syndrome, RAR index, red blood cell distribution width, albumin, biomarker, NHANES, UK Biobank, cardiovascular disease, chronic kidney disease, inflammation, risk stratification, metabolic syndrome